Thrombotic microangiopathy

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
4 Unique sponsors
3 Unique IMPs
4 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
Complement inhibitor (C5) 1 substance
Unknown / small molecule 1 substance
Phase III: 1 Phase II: 2 Phase I/II: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Alexion Pharmaceuticals Inc. Commercial
    RAVULIZUMAB
    2023-510107-22-00 9 countries 2020 n=61
    Ended

Phase II

2 trials
  • Omeros Corp. Commercial
    NARSOPLIMAB
    2023-509710-11-00 3 countries 2023 n=5 Orphan
    Recruiting
  • Swedish Orphan Biovitrum AB (publ) Commercial
    IMP not specified
    2023-510443-37-00 4 countries 2022 n=12
    Ended

Phase I/II

1 trial
  • TargED Biopharmaceuticals B.V. Commercial
    UROKINASE, CATALYTIC DOMAIN, FUSED WITH A SINGLE-CHAIN ANTIBODY AGAINST VON WILLEBRAND FACTOR
    2025-523802-34-00 4 countries n=40 Orphan
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Omeros Corp. Commercial 1 Phase II 1
Swedish Orphan Biovitrum AB (publ) Commercial 1 Phase II 0
Alexion Pharmaceuticals Inc. Commercial 1 Phase III 0
TargED Biopharmaceuticals B.V. Commercial 1 Phase I/II 0
New trials by year
2020
1
2022
1
2023
1
← All indication landscapes